Moleculin Biotech, Inc. (MBRX) News
Track canonical SquawkNews coverage tagged to MBRX, Moleculin Biotech, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Moleculin Prices $9.3M Public Offering
Moleculin announces $9.3 million public offering
EQUITY | Jul 31, 2026, 02:12 PM UTC
H
MBRX: No Cardiotoxicity Found
MBRX reports no cardiotoxicity with annamycin
EQUITY | Jul 31, 2026, 12:10 PM UTC
L
MBRX moleculin’s miracle R/r aml trial reports positive interim data with 37% blinded crc in venetoclax-failed patients
MBRX moleculin’s miracle R/r aml trial reports positive interim data with 37% blinded crc in venetoclax-failed patients
EQUITY | Jul 31, 2026, 12:10 PM UTC
M
MBRX Files Form S-1
MBRX files Form S-1 for common stock
FX | Jul 29, 2026, 01:45 PM UTC
L
Moleculin CEO Highlights Preliminary Unblinded Efficacy Results From First 45 Patients Enrolled In Part A Of Pivotal Phase 2/3 MIRACLE Trial
Moleculin Biotech, Inc., (NASDAQ: MBRX ) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What This Means" segment.
EQUITY | Jul 06, 2026, 12:47 PM UTC
L
Why is Moleculin Stock Falling Today?
Moleculin Biotech Inc. (NASDAQ: MBRX ) stock is trading lower on Tuesday after the company shared preliminary efficacy data from the first 45 patients enrolled in Part A of its pivotal Phase 2/3 MIRACLE trial that did no
EQUITY | Jun 30, 2026, 06:00 PM UTC
L
Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remis
Moleculin Biotech, Inc., (Nasdaq: MBRX ) ("Moleculin" or the "Company"), today announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the Company's pivotal Phase 2/3 MI
EQUITY | Jun 30, 2026, 12:34 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Tuesday's intraday session, with Aditxt and Atlantic International leading the gainers and Trinity Biotech and Tenon Medical leading the losers
EQUITY | Jun 23, 2026, 05:09 PM UTC